Nationwide study of drug resistance among acid-fast bacilli positive pulmonary tuberculosis cases in Lebanon

International Journal of Tuberculosis and Lung Disease

Volumn 10, Issue 1, 2006, Pages 63-67

  Araj, George F ^a,c   Saade, M ^b   Itani, L Y ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b MINISTRY OF PUBLIC HEALTH   (Lebanon)

^c NONE   (Lebanon)

Author keywords

Drugs; Mycobacterium tuberculosis; New TB cases; Resistance; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ACID FAST BACTERIUM; ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; LEBANON; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SPUTUM CULTURE; SPUTUM SMEAR; TUBERCULOSIS;

ADULT; AGED; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INCIDENCE; LEBANON; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 33144482512     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Cegielski P P, Chin D P, Espinal M A, et al. The global tuberculosis situation. Progress and problems in the 20th century, prospects for the 21st century. Infect Dis Clin North Am 2002; 16: 1-58.
2. Aziz M A, Wright A, De Muynck A, Laszlo A. Anti-tuberculosis drug resistance in the world. Third global report 1999-2002. WHO/HTM/TB/2004.343. Geneva, Switzerland: World Health Organization, 2004.
3. Hamze M M, Araj G F. Drug resistance among Mycobacterium tuberculosis isolates in Lebanon. Int J Tuberc Lung Dis 1997; 1: 314-318.
4. Araj G F, Itani L Y, Kanj N A, Jamaleddine G W. Comparative study of antituberculous drug resistance among Mycobacterium tuberculosis recovered at the American University of Beirut Medical Center: 1996-98 vs. 1994-95. Leb Med J 2000; 48: 18-22.
5. Aziz M A, Laszlo A, Raviglione M, Rieder H, Espinal M, Wright A. Guidelines for surveillance of drug resistance in tuberculosis. WHO/TB/2003.320. Geneva, Switzerland: World Health Organization, 2003.
6. Metchock B G, Nolte F S, Wallace R J, Jr. Mycobacterium. In: Murray P R, Baron E J, Pfaller M A, Tenover F C, Yolken R H, eds. Manual of Clinical Microbiology. 7th ed. Washington, DC, USA: American Society for Microbiology, 1999: pp 399-437.
7. Siddiqi S H. BACTEC TB SYSTEM Product and Procedure Manual. Sparks, MD, USA: Becton-Dickinson, 1995.
8. Heifets L. Dilemmas and realities of rapid diagnostic tests for tuberculosis. Chest 2002; 118: 4-5.
9. Aber V R, Allen B W, Mitcheson D A, Ayuma P, Edwards E A, Keyes A B. Quality control in tuberculosis bacteriology: 1. laboratory studies on isolated positive cultures and the efficiency of direct smear examination. Tubercle 1980; 61: 123-133.
10. IO Siddiqi K, Lambert M L, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. Lancet Inect Dis 2003; 3: 288-296.
11. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359-1374.
12. Beher M A, Warren S A, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999; 353: 444-449.
13. Araj G F. Tuberculosis: resurging disease with new dimensions-current status and new trends in laboratory diagnosis. Leb Med J 1994; 42: 126-133.
14. Enarson D A. Children and the global tuberculosis situation. Fed Respir Rev 2004; 5 (Suppl 1): S143-S145.
15. Abu-Amero K K. Review of the current status of drug-resistant tuberculosis in Saudi Arabia. Ann Saud Med 2002; 22: 236-238.
16. Al-Hajoj S A, Alrabiah F A. Role of tuberculosis laboratories in Saudi Arabia: a call to implement standardized procedures. Saudi Med J 2004; 25: 1545-1548.
17. Al Marri M R. Pattern of mycobacterial resistance to four antituberculosis drugs in pulmonary tuberculosis patients in the state of Qatar after the implementation of DOTS and a limited expatriate screening programme. Int J Tuberc Lung Dis 2001; 5: 1116-1121.
18. Kartaloglu Z, Bozkanat E, Ozturkeri H, Okutan O, Ilvan A. Primary antituberculosis drug resistance at Turkish Military Hospital in Istanbul. Med Principles Pract 2002; 11: 20-25.
19. Trébucq A, Anagonou S, Gninafon M, Lambregts K, Boulahbal F. Prevalence of primary and acquired resistance of Mycobacterium tuberculosis to antituberculosis drugs in Benin after 12 years of short-course chemotherapy. Int J Tuberc Lung Dis 1999; 3: 466-470.
20. Migliori G B, Centis R, Fattorini L, et al. Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998-2000. Eur Respir J 2003; 21: 129-134.
21. Morbidity & Mortality Weekly Report. Trends in tuberculosis morbidity-United States, 1992-2002. MMWR 2003; 52:217-222.
22. Willcox P A. Drug resistance tuberculosis: worldwide trends problems specific to Eastern Europe and other hotspots, and the threat to developing countries. Curr Opin Pulm Med 2001; 7: 148-153.
23. Guidelines for the management of drug-resistance tuberculosis. WHO/TB/96.210 (rev 1). Geneva, Switzerland: World Health Organization, 1997: pp 1-47.